ReviewJournal of cellular and molecular medicine2008
Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.
Review in Journal of cellular and molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.Molecular biomedicine · 2026Review
- PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb).Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Research Progress of Bioactive Peptides Derived from Traditional Natural Products in China.Molecules (Basel, Switzerland) · 2023Review
- Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis.International journal of molecular sciences · 2023Review
- The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.Drug design, development and therapy · 2023Article
- Neuropathophysiological Mechanisms and Treatment Strategies for Post-traumatic Epilepsy.Frontiers in molecular neuroscience · 2021Review
- The role of Th17 immunity in chronic ocular surface disorders.The ocular surface · 2021Review
- Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Peptides as Therapeutic Agents for Inflammatory-Related Diseases.International journal of molecular sciences · 2018Review
- Omega-3 fatty acids as an adjunct for periodontal therapy-a review.Clinical oral investigations · 2016Review
- Induction of omega 6 inflammatory pathway by sodium metabisulfite in rat liver and its attenuation by ghrelin.Lipids in health and disease · 2015Article
- Natural resolution of inflammation.Periodontology 2000 · 2013Review
- Resolvins and inflammatory pain.F1000 medicine reports · 2011Article
- Constitutive, but not challenge-induced, interleukin-10 production is robust in acute pre-pubescent protein and energy deficits: new support for the tolerance hypothesis of malnutrition-associated immune depression based on cytokine production in vivo.International journal of environmental research and public health · 2011Article
- Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.Current opinion in pharmacology · 2010Review
- Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels.Molecular and cellular biology · 2010Article
- Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages.Journal of cellular and molecular medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of the factors that regulate the immune tolerance and control the appearance of exacerbated inflammatory conditions is crucial for the development of new therapies of inflammatory and autoimmune diseases. Although much is known about the molecular basis of initiating signals and pro-inflammatory chemical mediators in inflammation, it has only recently become apparent that endogenous stop signals are critical at early checkpoints within the temporal events of inflammation. Some neuropeptides and lipid mediators that are produced during the ongoing inflammatory response have emerged as endogenous anti-inflammatory agents that participate in the regulation of the processes that ensure self-tolerance and/or inflammation resolution. Here we examine the latest research findings, which indicate that neuropeptides participate in maintaining immune tolerance in two distinct ways: by regulating the balance between pro-inflammatory and anti-inflammatory factors, and by inducing the emergence of regulatory T cells with suppressive activity against autoreactive T-cell effectors. On the other hand, we also focus on lipid mediators biosynthesized from omega-3 and omega-6 polyunsaturated fatty-acids in inflammatory exudates that promote the resolution phase of acute inflammation by regulating leucocyte influx to and efflux from local inflamed sites. Both anti-inflammatory neuropeptides and pro-resolving lipid mediators have shown therapeutic potential for a variety of inflammatory and autoimmune disorders and could be used as biotemplates for the development of novel pharmacologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.